JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 45(2011) N 3 p. 417-420;
E.V. Filatova1*, M.I. Shadrina1, A.V. Karabanov2, P.A. Slominsky1, S.N. Illarioshkin2, I.A. Ivanova-Smolenskaya2, S.A. Limborska1

Expression of GSK3B in Peripheral Blood of Patients with Parkinson's Disease

1Institute of Molecular Genetics RAS, Moscow, 123182
2Scientific Centre of Neurology of RAMS, Moscow, 125367

*FilatovaEV@img.ras.ru
Received - 2010-06-24; Accepted - 2010-09-27

Parkinson's disease (PD) is the second most common progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons. Detecting changes in gene expression in untreated de novo patients with PD is important for understanding the disease pathogenesis and for identifying biomarkers of the preclinical stage of PD. In this study, the expression of the glycogen synthase kinase-3 beta gene (GSK3B) was investigated in the peripheral blood of several groups of neurological patients using reverse transcription reaction and real-time PCR. Our results suggest that the GSK3B expression level cannot serve as a biomarker for early stages of PD.

expression level, GSK3B, Parkinson's disease, real-time polymerase chain reaction



JMB-FOOTER RAS-JOURNALS